The effect of other complement C5 inhibitors, eculizumab and ravulizumab, on fatigue in their Phase 3 and OLE studies was assessed using the raw scores on an alternative, longer instrument—the 19-item Neuro-QoL fatigue subscale—and variable degrees of reduction from baseline were reported, highlighting that complement C5 inhibitors can reduce fatigue in patients with MG [28–30]. The gene discussed is C5; the disease is myasthenia gravis.